Evidence map›Paper›PMID 42465267›Full record

ArticlebioRxiv : the preprint server for biology2026

PSGL-1 blockade delays relapse to BRAF/MEK inhibition in cutaneous melanoma.

O S El Naggar, B N Ha, M L Rakoto, L Cort, A Amirfallah, E A Haglund, P Urquiza, Haf Hetrick, L M Bradley, E J Hartsough and 2 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

O S El NaggarDepartment of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, PA 19102.
B N HaDepartment of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, PA 19102.
M L RakotoDepartment of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA 19102.
L CortDepartment of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA 19102.
A AmirfallahDepartment of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, PA 19102.
E A HaglundDepartment of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA 19102.
P UrquizaDepartment of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, PA 19102.
Haf HetrickCancer Metabolism and Microenvironment Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037.
L M BradleyCancer Metabolism and Microenvironment Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037.
E J HartsoughDepartment of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, PA 19102.
J L HopeDepartment of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA 19102.
G RomanoDepartment of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, PA 19102.

Funding

Exploiting oxidative stress response in uveal melanoma liver metastasesR01CA282901 · NCI · DREXEL UNIVERSITY · PI Edward Hartsough · 2024 to 2026
$1.4M
NCI NIH HHS R01 CA282901
6 · The paper itself

Abstract

Advanced BRAF-mutant cutaneous melanoma can be treated with targeted therapy when immune checkpoint inhibitors (ICIs) fail or are not a feasible option. Nevertheless, most patients do not achieve a durable response, highlighting the critical need for therapeutic partners that enhance the long-term efficacy of targeted therapy. Transcriptomic analysis of a BRAF-mutant melanoma model of acquired resistance identified P-selectin glycoprotein ligand-1 (PSGL-1) as a top-upregulated immune mediator upon resistance acquisition. PSGL-1 is a key regulator of CD8

Indexed as

BRAFimmunotherapymelanomatargeted therapyT cells

Identifiers

PMID42465267
PMCPMC13371076

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.